
The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy
Keywords: اورولیموس; Epilepsy; Rapamycin; Everolimus; Pharmacokinetics; Tolerability; Levetiracetam; AKT; protein kinase B; ASD; anti-seizure drug; 4E-BP1; initiation factor 4E binding protein; HPβCD; hydroxypropyl-Ã-cyclodextrin; MTD; maximal tolerated dose; MES-T; maximal